CareTria

Caretria is a precision oncology company developing a functional diagnostic platform designed to predict patient response to cancer therapies. By utilizing microfluidic technology to maintain the viability and microenvironment of patient-derived tumor tissue, the company's platform enables the direct testing of various therapeutic agents ex vivo. This approach aims to provide clinicians with actionable data to select the most effective treatments for individual patients, moving beyond the limitations of genomic-only profiling. Caretria's technology focuses on capturing the complex, real-time interactions within the tumor to improve the accuracy of treatment predictions across a range of solid tumors.